Tiagabine May Reduce Bruxism and Associated Temporomandibular Joint Pain

Kast, R. E.

doi:10.2344/0003-3006(2005)52[102:tmrbaa]2.0.co;2

Cited by 28 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, the role of GABA in the occurrence of SB is more clear. GABA‐related drugs such as diazepam, gabapentin, tiagabine and gamma‐hydroxybutyrate have been shown to decrease the occurrence of SB, and these effects might be related to improvements of sleep and reduction of cortical arousals during sleep . This suggests that GABA may be critically important to the occurrence of SB.…”

Section: Discussionmentioning

confidence: 99%

Characterisation of the relationships between rhythmic masticatory muscle activities and limb movements in patients with sleep bruxism

Han

Wang

Zhong

et al. 2019

J of Oral Rehabilitation

View full text Add to dashboard Cite

Summary Background Most rhythmic masticatory muscle activities (RMMAs) have been shown to be accompanied with limb movements (LMs) in sleep bruxism (SB) patients during sleep. Objectives To compare the relationships between RMMAs and LMs in SB patients and normal subjects. Methods Polysomnographic recordings were performed on eight SB patients and nine normal subjects and the frequencies and durations of RMMAs as well as LMs were determined. Linear regression and correlation analysis were performed to study the relationship between durations of RMMAs and LMs when RMMAs occurred with LMs. Results Most LMs in SB patients, but not in normal subjects, were accompanied with RMMAs. RMMAs in SB patients were more likely to be isolated, phasic or mixed, while RMMAs in normal subjects were more likely to be tonic. The frequencies of LMs, isolated RMMAs and RMMAs accompanied with LMs in SB patients were significantly higher than those in normal subjects. Furthermore, linear regression and correlation analysis showed that duration of RMMAs was significantly associated with that of LMs when RMMAs occurred with LMs. The duration of RMMAs, when accompanied with LMs, in SB patients was significantly longer than that in normal subjects. Conclusions Close relationships between LMs and RMMAs exist in SB patients and normal subjects, and SB episodes may be part of cortical arousal responses and the increased cortical activities associated with SB episodes may not just be localised to the central nervous system (CNS) that controls jaw movements but may also include other parts of CNS that controls LMs.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterisation of the relationships between rhythmic masticatory muscle activities and limb movements in patients with sleep bruxism

Han

Wang

Zhong

et al. 2019

J of Oral Rehabilitation

View full text Add to dashboard Cite

show abstract

“…Gabapentin was successfully applied for the treatment of a 50‐year‐old man who suffered from bruxism, induced by venlafaxine (an antidepressant; see below) (136). Likewise, self‐reported bruxism was successfully managed with tiagabine in four of five cases described by Kast (137). Unfortunately, no RCT are available to assess the efficacy and safety of anticonvulsant drugs in the management of bruxism.…”

Section: Pharmacological Approachesmentioning

confidence: 91%

Principles for the management of bruxism*

Lobbezoo

Zaag

Selms

et al. 2008

J of Oral Rehabilitation

244

202

View full text Add to dashboard Cite

Summary The management of bruxism has been the subject of a large number of studies. A PubMed search, using relevant MeSH terms, yielded a total of 177 papers that were published over the past 40 years. Of these papers, 135 were used for the present review. Apparently, research into bruxism management is sensitive to fashion. Interest in studying the role of occlusal interventions and oral splints in the treatment of bruxism remained more or less constant over the years: between 1966 and 2007, approximately 40–60% of the papers dealt with this subject. The percentage of papers that dealt with behavioural approaches, on the other hand, declined from >60% in the first 2 decades (1966–1986) to only slightly >10% in the most recent decade (1997–2007). In the latter period, >40% of the papers studied the role of various medicines in the treatment of bruxism, while in the preceding decade (1987–1996), only approximately 5% of the studies dealt with the pharmacological management of bruxism. Unfortunately, a vast majority of the 135 papers have a too low level of evidence. Only 13% of the studies used a randomized clinical trial design, and even these trials do not yet provide clinicians with strong, evidence‐based recommendations for the treatment of bruxism. Hence, there is a vast need for well‐designed studies. Clinicians should be aware of this striking paucity of evidence regarding management of bruxism.

show abstract

“…Overwhelming evidence indicates that some antiepileptic drugs, especially, gabapentin and tiagabine exert analgesic effects in both, preclinical studies on animals and clinical settings in humans. Quite recently, it has been reported that tiagabine is effective in patients with painful sensory neuropathy (Novak et al, 2001), painful tonic spasm (Solaro and Tanganelli, 2004), bruxism (Kast, 2005) and chronic pain (Todorov et al, 2005). Similarly, gabapentin is effective in suppressing and alleviating pain in postherpetic neuralgia (Garry et al, 2005; Rowbotham et al, 1998), painful diabetic neuropathy (Backonja et al, 1998), migraine (Di Trapani et al, 2000), reflex sympathetic dystrophy (Mellick and Mellick, 1997), trigeminal neuralgia (Sist et al, 1997) and neuropathic cancer pain (Caraceni et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Synergistic interaction of gabapentin with tiagabine in the formalin test in mice: An isobolographic analysis

Łuszczki

Kolacz

Czuczwar

et al. 2009

European Journal of Pain

View full text Add to dashboard Cite

The aim of this study was to determine the analgesic effect of gabapentin and tiagabine - two antiepileptic drugs, administered alone and in combination at the fixed-ratio of 1:1, in two phases of the formalin test in mice. Log-probit analysis was used to evaluate dose-response effects and calculate the ED(50) values for gabapentin, tiagabine, and their combination at the fixed-ratio of 1:1 in the phases I and II of the formalin test in mice. The types of interactions between both antiepileptic drugs were characterized using the isobolographic analysis. Results indicated that gabapentin and tiagabine produced the antinociceptive effect in both phases of the formalin test. The ED(50) values for gabapentin and tiagabine, administered singly, in the phase I of the formalin test were 29.59 and 2mg/kg, whereas in the phase II of the formalin test were 8.22 and 0.50 mg/kg, respectively. With isobolography, the ED(50 mix) values at the fixed-ratio combination of 1:1 were 7.30 mg/kg (phase I) and 0.48 mg/kg (phase II), indicating both additive and supra-additive (synergistic) interactions between gabapentin and tiagabine in the formalin test in mice. In conclusion, the combination of gabapentin with tiagabine at the fixed-ratio of 1:1 exerted additive interaction in the phase I and synergistic interaction in the phase II of the formalin test in mice. If the results from this study could be extrapolated to clinical settings, the combination of tiagabine with gabapentin might be beneficial in the pain relief in humans.

show abstract

Tiagabine May Reduce Bruxism and Associated Temporomandibular Joint Pain

Cited by 28 publications

References 19 publications

Characterisation of the relationships between rhythmic masticatory muscle activities and limb movements in patients with sleep bruxism

Characterisation of the relationships between rhythmic masticatory muscle activities and limb movements in patients with sleep bruxism

Principles for the management of bruxism*

Synergistic interaction of gabapentin with tiagabine in the formalin test in mice: An isobolographic analysis

Contact Info

Product

Resources

About